ID   TUT4_HUMAN              Reviewed;        1644 AA.
AC   Q5TAX3; A2RRP0; B7Z8J5; D3DQ35; Q12764; Q5TAX2; Q5TAX4; Q86XZ3;
DT   10-MAY-2005, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   28-JUN-2023, entry version 157.
DE   RecName: Full=Terminal uridylyltransferase 4 {ECO:0000305};
DE            Short=TUTase 4;
DE            EC=2.7.7.52 {ECO:0000269|PubMed:19703396, ECO:0000269|PubMed:31036859};
DE   AltName: Full=Zinc finger CCHC domain-containing protein 11;
GN   Name=TUT4 {ECO:0000312|HGNC:HGNC:28981};
GN   Synonyms=KIAA0191, ZCCHC11 {ECO:0000312|HGNC:HGNC:28981};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 129-1644.
RC   TISSUE=Bone marrow;
RX   PubMed=8724849; DOI=10.1093/dnares/3.1.17;
RA   Nagase T., Seki N., Ishikawa K., Tanaka A., Nomura N.;
RT   "Prediction of the coding sequences of unidentified human genes. V. The
RT   coding sequences of 40 new genes (KIAA0161-KIAA0200) deduced by analysis of
RT   cDNA clones from human cell line KG-1.";
RL   DNA Res. 3:17-24(1996).
RN   [6]
RP   FUNCTION, INTERACTION WITH T2BP, AND SUBCELLULAR LOCATION.
RX   PubMed=16643855; DOI=10.1016/j.bbrc.2006.04.006;
RA   Minoda Y., Saeki K., Aki D., Takaki H., Sanada T., Koga K., Kobayashi T.,
RA   Takaesu G., Yoshimura A.;
RT   "A novel Zinc finger protein, ZCCHC11, interacts with TIFA and modulates
RT   TLR signaling.";
RL   Biochem. Biophys. Res. Commun. 344:1023-1030(2006).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [8]
RP   ABSENCE OF FUNCTION IN HISTONE MRNA DEGRADATION ACTIVITY.
RX   PubMed=18172165; DOI=10.1101/gad.1622708;
RA   Mullen T.E., Marzluff W.F.;
RT   "Degradation of histone mRNA requires oligouridylation followed by
RT   decapping and simultaneous degradation of the mRNA both 5' to 3' and 3' to
RT   5'.";
RL   Genes Dev. 22:50-65(2008).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, INTERACTION WITH
RP   LIN28A, AND MUTAGENESIS OF ASP-1011.
RX   PubMed=19703396; DOI=10.1016/j.cell.2009.08.002;
RA   Heo I., Joo C., Kim Y.-K., Ha M., Yoon M.-J., Cho J., Yeom K.-H., Han J.,
RA   Kim V.N.;
RT   "TUT4 in concert with Lin28 suppresses MicroRNA biogenesis through pre-
RT   microRNA uridylation.";
RL   Cell 138:696-708(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   INTERACTION WITH LIN28A.
RX   PubMed=22118463; DOI=10.1016/j.cell.2011.10.039;
RA   Piskounova E., Polytarchou C., Thornton J.E., LaPierre R.J.,
RA   Pothoulakis C., Hagan J.P., Iliopoulos D., Gregory R.I.;
RT   "Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct
RT   mechanisms.";
RL   Cell 147:1066-1079(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-104 AND SER-156, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASP-1011.
RX   PubMed=25480299; DOI=10.1016/j.cell.2014.10.055;
RA   Lim J., Ha M., Chang H., Kwon S.C., Simanshu D.K., Patel D.J., Kim V.N.;
RT   "Uridylation by TUT4 and TUT7 marks mRNA for degradation.";
RL   Cell 159:1365-1376(2014).
RN   [14]
RP   FUNCTION.
RX   PubMed=25979828; DOI=10.15252/embj.201590931;
RA   Kim B., Ha M., Loeff L., Chang H., Simanshu D.K., Li S., Fareh M.,
RA   Patel D.J., Joo C., Kim V.N.;
RT   "TUT7 controls the fate of precursor microRNAs by using three different
RT   uridylation mechanisms.";
RL   EMBO J. 34:1801-1815(2015).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH MOV10, AND MUTAGENESIS OF
RP   ASP-1011.
RX   PubMed=30122351; DOI=10.1016/j.cell.2018.07.022;
RA   Warkocki Z., Krawczyk P.S., Adamska D., Bijata K., Garcia-Perez J.L.,
RA   Dziembowski A.;
RT   "Uridylation by TUT4/7 Restricts Retrotransposition of Human LINE-1s.";
RL   Cell 0:0-0(2018).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 253-723 IN COMPLEX WITH ZINC
RP   IONS, FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH LIN28A AND PRE-LET-7
RP   RNA, AND MUTAGENESIS OF 253-SER--LEU-333; CYS-306; CYS-309; LYS-321;
RP   LYS-324; 326-LYS-ARG-327; 329-LYS-LYS-330; HIS-450; LYS-452 AND
RP   669-ARG-ARG-670.
RX   PubMed=31036859; DOI=10.1038/s41467-019-09966-5;
RA   Yamashita S., Nagaike T., Tomita K.;
RT   "Crystal structure of the Lin28-interacting module of human terminal
RT   uridylyltransferase that regulates let-7 expression.";
RL   Nat. Commun. 10:1960-1960(2019).
CC   -!- FUNCTION: Uridylyltransferase that mediates the terminal uridylation of
CC       mRNAs with short (less than 25 nucleotides) poly(A) tails, hence
CC       facilitating global mRNA decay (PubMed:25480299, PubMed:31036859).
CC       Essential for both oocyte maturation and fertility. Through 3' terminal
CC       uridylation of mRNA, sculpts, with TUT7, the maternal transcriptome by
CC       eliminating transcripts during oocyte growth (By similarity). Involved
CC       in microRNA (miRNA)-induced gene silencing through uridylation of
CC       deadenylated miRNA targets. Also functions as an integral regulator of
CC       microRNA biogenesis using 3 different uridylation mechanisms
CC       (PubMed:25979828). Acts as a suppressor of miRNA biogenesis by
CC       mediating the terminal uridylation of some miRNA precursors, including
CC       that of let-7 (pre-let-7), miR107, miR-143 and miR-200c. Uridylated
CC       miRNAs are not processed by Dicer and undergo degradation. Degradation
CC       of pre-let-7 contributes to the maintenance of embryonic stem (ES) cell
CC       pluripotency (By similarity). Also catalyzes the 3' uridylation of miR-
CC       26A, a miRNA that targets IL6 transcript. This abrogates the silencing
CC       of IL6 transcript, hence promoting cytokine expression
CC       (PubMed:19703396). In the absence of LIN28A, TUT7 and TUT4
CC       monouridylate group II pre-miRNAs, which includes most of pre-let7
CC       members, that shapes an optimal 3' end overhang for efficient
CC       processing (PubMed:25979828). Adds oligo-U tails to truncated pre-
CC       miRNAS with a 5' overhang which may promote rapid degradation of non-
CC       functional pre-miRNA species (PubMed:25979828). May also suppress Toll-
CC       like receptor-induced NF-kappa-B activation via binding to T2BP
CC       (PubMed:16643855). Does not play a role in replication-dependent
CC       histone mRNA degradation (PubMed:18172165). Due to functional
CC       redundancy between TUT4 and TUT7, the identification of the specific
CC       role of each of these proteins is difficult (PubMed:25979828,
CC       PubMed:25480299, PubMed:16643855, PubMed:19703396, PubMed:18172165) (By
CC       similarity). TUT4 and TUT7 restrict retrotransposition of long
CC       interspersed element-1 (LINE-1) in cooperation with MOV10 counteracting
CC       the RNA chaperonne activity of L1RE1. TUT7 uridylates LINE-1 mRNAs in
CC       the cytoplasm which inhibits initiation of reverse transcription once
CC       in the nucleus, whereas uridylation by TUT4 destabilizes mRNAs in
CC       cytoplasmic ribonucleoprotein granules (PubMed:30122351).
CC       {ECO:0000250|UniProtKB:B2RX14, ECO:0000269|PubMed:16643855,
CC       ECO:0000269|PubMed:18172165, ECO:0000269|PubMed:19703396,
CC       ECO:0000269|PubMed:25480299, ECO:0000269|PubMed:25979828,
CC       ECO:0000269|PubMed:30122351, ECO:0000269|PubMed:31036859}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=RNA(n) + UTP = diphosphate + RNA(n)-3'-uridine ribonucleotide;
CC         Xref=Rhea:RHEA:14785, Rhea:RHEA-COMP:14527, Rhea:RHEA-COMP:17348,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:46398, ChEBI:CHEBI:140395,
CC         ChEBI:CHEBI:173116; EC=2.7.7.52;
CC         Evidence={ECO:0000269|PubMed:19703396, ECO:0000269|PubMed:31036859};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Interacts with LIN28A in the presence of pre-let-7 RNA
CC       (PubMed:19703396, PubMed:22118463, PubMed:31036859). Interacts with
CC       T2BP (PubMed:16643855). Interacts with MOV10; the interaction is RNA-
CC       dependent (PubMed:30122351). {ECO:0000269|PubMed:16643855,
CC       ECO:0000269|PubMed:19703396, ECO:0000269|PubMed:22118463,
CC       ECO:0000269|PubMed:30122351, ECO:0000269|PubMed:31036859}.
CC   -!- INTERACTION:
CC       Q5TAX3-1; Q96CG3: TIFA; NbExp=2; IntAct=EBI-1606425, EBI-740711;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:16643855}. Cytoplasm
CC       {ECO:0000269|PubMed:16643855, ECO:0000269|PubMed:19703396,
CC       ECO:0000269|PubMed:25480299}. Cytoplasm, Cytoplasmic ribonucleoprotein
CC       granule {ECO:0000269|PubMed:30122351}. Note=Mainly cytoplasmic
CC       (PubMed:19703396, PubMed:25480299). Translocates into the cytoplasm
CC       following treatment of the cell with LPS (PubMed:16643855). Co-enriched
CC       in cytoplasmic foci with MOV10 (PubMed:30122351).
CC       {ECO:0000269|PubMed:30122351}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q5TAX3-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q5TAX3-2; Sequence=VSP_038135, VSP_038136;
CC   -!- DOMAIN: Utilizes two multidomain functional modules during the switch
CC       from monouridylation to oligouridylation. The catalytic module
CC       (containing the 3 CCHC-type Zinc finger domains) is essential for both
CC       activities while the Lin28-interacting module (LIM) at the N-termail
CC       part is indispensable for oligouridylation.
CC       {ECO:0000250|UniProtKB:B2RX14}.
CC   -!- SIMILARITY: Belongs to the DNA polymerase type-B-like family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK303532; BAH13981.1; -; mRNA.
DR   EMBL; AL138849; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471059; EAX06778.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX06780.1; -; Genomic_DNA.
DR   EMBL; BC131734; AAI31735.1; -; mRNA.
DR   EMBL; D83776; BAA12105.1; -; mRNA.
DR   CCDS; CCDS30716.1; -. [Q5TAX3-1]
DR   RefSeq; NP_001009881.1; NM_001009881.2.
DR   RefSeq; NP_056084.1; NM_015269.2. [Q5TAX3-1]
DR   PDB; 6IW6; X-ray; 2.40 A; A/B=253-723.
DR   PDBsum; 6IW6; -.
DR   AlphaFoldDB; Q5TAX3; -.
DR   SMR; Q5TAX3; -.
DR   BioGRID; 116909; 81.
DR   IntAct; Q5TAX3; 16.
DR   MINT; Q5TAX3; -.
DR   STRING; 9606.ENSP00000257177; -.
DR   GlyGen; Q5TAX3; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q5TAX3; -.
DR   PhosphoSitePlus; Q5TAX3; -.
DR   BioMuta; ZCCHC11; -.
DR   DMDM; 116242850; -.
DR   EPD; Q5TAX3; -.
DR   jPOST; Q5TAX3; -.
DR   MassIVE; Q5TAX3; -.
DR   MaxQB; Q5TAX3; -.
DR   PaxDb; Q5TAX3; -.
DR   PeptideAtlas; Q5TAX3; -.
DR   ProteomicsDB; 64876; -. [Q5TAX3-1]
DR   ProteomicsDB; 64877; -. [Q5TAX3-2]
DR   Antibodypedia; 19117; 235 antibodies from 32 providers.
DR   DNASU; 23318; -.
DR   Ensembl; ENST00000371544.7; ENSP00000360599.3; ENSG00000134744.14. [Q5TAX3-1]
DR   GeneID; 23318; -.
DR   KEGG; hsa:23318; -.
DR   UCSC; uc001ctx.3; human. [Q5TAX3-1]
DR   AGR; HGNC:28981; -.
DR   CTD; 23318; -.
DR   DisGeNET; 23318; -.
DR   GeneCards; TUT4; -.
DR   HGNC; HGNC:28981; TUT4.
DR   HPA; ENSG00000134744; Low tissue specificity.
DR   MIM; 613692; gene.
DR   neXtProt; NX_Q5TAX3; -.
DR   OpenTargets; ENSG00000134744; -.
DR   PharmGKB; PA134918178; -.
DR   VEuPathDB; HostDB:ENSG00000134744; -.
DR   eggNOG; KOG2277; Eukaryota.
DR   GeneTree; ENSGT00940000156988; -.
DR   InParanoid; Q5TAX3; -.
DR   OrthoDB; 170176at2759; -.
DR   PhylomeDB; Q5TAX3; -.
DR   TreeFam; TF315661; -.
DR   BRENDA; 2.7.7.52; 2681.
DR   PathwayCommons; Q5TAX3; -.
DR   Reactome; R-HSA-429947; Deadenylation of mRNA.
DR   SignaLink; Q5TAX3; -.
DR   SIGNOR; Q5TAX3; -.
DR   BioGRID-ORCS; 23318; 17 hits in 1161 CRISPR screens.
DR   ChiTaRS; ZCCHC11; human.
DR   GenomeRNAi; 23318; -.
DR   Pharos; Q5TAX3; Tbio.
DR   PRO; PR:Q5TAX3; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q5TAX3; protein.
DR   Bgee; ENSG00000134744; Expressed in right hemisphere of cerebellum and 189 other tissues.
DR   ExpressionAtlas; Q5TAX3; baseline and differential.
DR   Genevisible; Q5TAX3; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0036464; C:cytoplasmic ribonucleoprotein granule; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0035198; F:miRNA binding; ISS:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0050265; F:RNA uridylyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0010587; P:miRNA catabolic process; IMP:UniProtKB.
DR   GO; GO:0010586; P:miRNA metabolic process; IDA:UniProtKB.
DR   GO; GO:0000289; P:nuclear-transcribed mRNA poly(A) tail shortening; TAS:Reactome.
DR   GO; GO:0001556; P:oocyte maturation; ISS:UniProtKB.
DR   GO; GO:1990074; P:polyuridylation-dependent mRNA catabolic process; ISS:UniProtKB.
DR   GO; GO:0031054; P:pre-miRNA processing; IDA:UniProtKB.
DR   GO; GO:0141008; P:retrotransposon silencing by mRNA destabilization; IDA:UniProtKB.
DR   GO; GO:0071076; P:RNA 3' uridylation; ISS:UniProtKB.
DR   GO; GO:0031123; P:RNA 3'-end processing; IDA:UniProtKB.
DR   GO; GO:0019827; P:stem cell population maintenance; IMP:UniProtKB.
DR   CDD; cd05402; NT_PAP_TUTase; 2.
DR   Gene3D; 1.10.1410.10; -; 2.
DR   Gene3D; 3.30.460.10; Beta Polymerase, domain 2; 2.
DR   Gene3D; 4.10.60.10; Zinc finger, CCHC-type; 1.
DR   InterPro; IPR043519; NT_sf.
DR   InterPro; IPR002058; PAP_assoc.
DR   InterPro; IPR002934; Polymerase_NTP_transf_dom.
DR   InterPro; IPR045100; TUTase_dom.
DR   InterPro; IPR001878; Znf_CCHC.
DR   InterPro; IPR036875; Znf_CCHC_sf.
DR   PANTHER; PTHR12271; POLY A POLYMERASE CID PAP -RELATED; 1.
DR   PANTHER; PTHR12271:SF49; TERMINAL URIDYLYLTRANSFERASE 4; 1.
DR   Pfam; PF01909; NTP_transf_2; 1.
DR   Pfam; PF03828; PAP_assoc; 2.
DR   Pfam; PF19088; TUTase; 1.
DR   Pfam; PF00098; zf-CCHC; 2.
DR   SMART; SM00343; ZnF_C2HC; 3.
DR   SUPFAM; SSF81301; Nucleotidyltransferase; 2.
DR   SUPFAM; SSF81631; PAP/OAS1 substrate-binding domain; 2.
DR   SUPFAM; SSF57756; Retrovirus zinc finger-like domains; 2.
DR   PROSITE; PS50158; ZF_CCHC; 3.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cytoplasm; Magnesium; Manganese;
KW   Metal-binding; Methylation; Nucleotidyltransferase; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; RNA-mediated gene silencing;
KW   Transferase; Zinc; Zinc-finger.
FT   CHAIN           1..1644
FT                   /note="Terminal uridylyltransferase 4"
FT                   /id="PRO_0000150970"
FT   DOMAIN          628..678
FT                   /note="PAP-associated 1"
FT   DOMAIN          1184..1237
FT                   /note="PAP-associated 2"
FT   ZN_FING         304..334
FT                   /note="Matrin-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00130"
FT   ZN_FING         913..930
FT                   /note="CCHC-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00047"
FT   ZN_FING         1293..1310
FT                   /note="CCHC-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00047"
FT   ZN_FING         1357..1374
FT                   /note="CCHC-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00047"
FT   REGION          31..63
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          96..168
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          205..257
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          253..333
FT                   /note="Required for interaction with LIN28A and pre-let-7
FT                   RNA"
FT                   /evidence="ECO:0000269|PubMed:31036859"
FT   REGION          579..617
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          794..816
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          901..1634
FT                   /note="Sufficient for monouridylation activity"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VYS8"
FT   REGION          1321..1348
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1401..1482
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        108..152
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        206..229
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        234..253
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        583..617
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         306
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:31036859"
FT   BINDING         309
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:31036859"
FT   BINDING         322
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:31036859"
FT   BINDING         328
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:31036859"
FT   BINDING         998..1001
FT                   /ligand="UTP"
FT                   /ligand_id="ChEBI:CHEBI:46398"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VYS8"
FT   BINDING         1008..1011
FT                   /ligand="UTP"
FT                   /ligand_id="ChEBI:CHEBI:46398"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VYS8"
FT   BINDING         1009
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000250"
FT   BINDING         1011
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000250"
FT   BINDING         1081
FT                   /ligand="UTP"
FT                   /ligand_id="ChEBI:CHEBI:46398"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VYS8"
FT   BINDING         1103
FT                   /ligand="UTP"
FT                   /ligand_id="ChEBI:CHEBI:46398"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VYS8"
FT   BINDING         1121..1125
FT                   /ligand="UTP"
FT                   /ligand_id="ChEBI:CHEBI:46398"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VYS8"
FT   BINDING         1237
FT                   /ligand="UTP"
FT                   /ligand_id="ChEBI:CHEBI:46398"
FT                   /evidence="ECO:0000250|UniProtKB:Q5VYS8"
FT   MOD_RES         104
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         134
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:B2RX14"
FT   MOD_RES         156
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1624
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:B2RX14"
FT   VAR_SEQ         685..719
FT                   /note="RSLNSQLVYEYVVERFRAAYRYFACPQTKGGNKST -> LQPGRQEWKLCLK
FT                   KKKKNSVKYTFIYEIQVSLFVI (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_038135"
FT   VAR_SEQ         720..1644
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_038136"
FT   VARIANT         796
FT                   /note="D -> Y (in dbSNP:rs12127732)"
FT                   /id="VAR_028402"
FT   MUTAGEN         253..333
FT                   /note="Missing: Loss of interaction with LIN28A and
FT                   pre-let-7 RNA."
FT                   /evidence="ECO:0000269|PubMed:31036859"
FT   MUTAGEN         306
FT                   /note="C->A: Loss of LIN28A and pre-let-7 RNA binding and
FT                   loss of pre-let-7 RNA uridylylation; when associated with
FT                   A-309."
FT                   /evidence="ECO:0000269|PubMed:31036859"
FT   MUTAGEN         309
FT                   /note="C->A: Loss of LIN28A and pre-let-7 RNA binding and
FT                   loss of pre-let-7 RNA uridylylation; when associated with
FT                   A-306."
FT                   /evidence="ECO:0000269|PubMed:31036859"
FT   MUTAGEN         321
FT                   /note="K->A: Strongly decreased LIN28A and pre-let-7 RNA
FT                   binding and pre-let-7 RNA uridylylation; when associated
FT                   with A-324."
FT                   /evidence="ECO:0000269|PubMed:31036859"
FT   MUTAGEN         324
FT                   /note="K->A: Strongly decreased LIN28A and pre-let-7 RNA
FT                   binding and pre-let-7 RNA uridylylation; when associated
FT                   with A-321."
FT                   /evidence="ECO:0000269|PubMed:31036859"
FT   MUTAGEN         326..327
FT                   /note="KR->AA: Strongly decreased LIN28A and pre-let-7 RNA
FT                   binding and pre-let-7 RNA uridylylation."
FT                   /evidence="ECO:0000269|PubMed:31036859"
FT   MUTAGEN         329..330
FT                   /note="KK->AA: Decreased LIN28A and pre-let-7 RNA binding
FT                   and pre-let-7 RNA uridylylation."
FT                   /evidence="ECO:0000269|PubMed:31036859"
FT   MUTAGEN         450
FT                   /note="H->A: Decreased LIN28A and pre-let-7 RNA binding and
FT                   pre-let-7 RNA uridylylation; when associated with A-452."
FT                   /evidence="ECO:0000269|PubMed:31036859"
FT   MUTAGEN         452
FT                   /note="K->A: Decreased LIN28A and pre-let-7 RNA binding and
FT                   pre-let-7 RNA uridylylation; when associated with A-450."
FT                   /evidence="ECO:0000269|PubMed:31036859"
FT   MUTAGEN         669..670
FT                   /note="RR->AA: Decreased LIN28A and pre-let-7 RNA binding
FT                   and pre-let-7 RNA uridylylation."
FT                   /evidence="ECO:0000269|PubMed:31036859"
FT   MUTAGEN         1011
FT                   /note="D->A: Loss of nucleotidyltransferase activity and
FT                   stabilization of pre-let-7 miRNAs. Abolishes inhibition of
FT                   LIRE1 retrotransposition."
FT                   /evidence="ECO:0000269|PubMed:19703396,
FT                   ECO:0000269|PubMed:25480299, ECO:0000269|PubMed:30122351"
FT   CONFLICT        1313
FT                   /note="S -> SS (in Ref. 4; AAI31735)"
FT                   /evidence="ECO:0000305"
FT   HELIX           255..260
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   TURN            266..268
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   HELIX           271..285
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   TURN            286..288
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   STRAND          289..291
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   STRAND          304..306
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   TURN            307..310
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   STRAND          311..313
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   HELIX           316..323
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   HELIX           326..342
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   HELIX           349..366
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   HELIX           370..388
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   STRAND          395..399
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   HELIX           401..404
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   STRAND          413..418
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   STRAND          421..423
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   HELIX           425..438
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   STRAND          442..448
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   STRAND          450..453
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   STRAND          455..460
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   TURN            461..463
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   STRAND          466..472
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   HELIX           474..489
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   HELIX           493..502
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   TURN            503..505
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   HELIX           506..509
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   HELIX           517..532
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   STRAND          533..535
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   STRAND          541..543
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   HELIX           554..556
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   STRAND          558..563
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   TURN            564..566
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   STRAND          567..571
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   STRAND          613..619
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   HELIX           629..641
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   TURN            646..648
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   STRAND          649..651
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   TURN            661..665
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   STRAND          673..675
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   STRAND          678..682
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   HELIX           683..687
FT                   /evidence="ECO:0007829|PDB:6IW6"
FT   HELIX           690..707
FT                   /evidence="ECO:0007829|PDB:6IW6"
SQ   SEQUENCE   1644 AA;  185166 MW;  B7C88D7DCF0F3356 CRC64;
     MEESKTLKSE NHEPKKNVIC EESKAVQVIG NQTLKARNDK SVKEIENSSP NRNSSKKNKQ
     NDICIEKTEV KSCKVNAANL PGPKDLGLVL RDQSHCKAKK FPNSPVKAEK ATISQAKSEK
     ATSLQAKAEK SPKSPNSVKA EKASSYQMKS EKVPSSPAEA EKGPSLLLKD MRQKTELQQI
     GKKIPSSFTS VDKVNIEAVG GEKCALQNSP RSQKQQTCTD NTGDSDDSAS GIEDVSDDLS
     KMKNDESNKE NSSEMDYLEN ATVIDESALT PEQRLGLKQA EERLERDHIF RLEKRSPEYT
     NCRYLCKLCL IHIENIQGAH KHIKEKRHKK NILEKQEESE LRSLPPPSPA HLAALSVAVI
     ELAKEHGITD DDLRVRQEIV EEMSKVITTF LPECSLRLYG SSLTRFALKS SDVNIDIKFP
     PKMNHPDLLI KVLGILKKNV LYVDVESDFH AKVPVVVCRD RKSGLLCRVS AGNDMACLTT
     DLLTALGKIE PVFIPLVLAF RYWAKLCYID SQTDGGIPSY CFALMVMFFL QQRKPPLLPC
     LLGSWIEGFD PKRMDDFQLK GIVEEKFVKW ECNSSSATEK NSIAEENKAK ADQPKDDTKK
     TETDNQSNAM KEKHGKSPLA LETPNRVSLG QLWLELLKFY TLDFALEEYV ICVRIQDILT
     RENKNWPKRR IAIEDPFSVK RNVARSLNSQ LVYEYVVERF RAAYRYFACP QTKGGNKSTV
     DFKKREKGKI SNKKPVKSNN MATNGCILLG ETTEKINAER EQPVQCDEMD CTSQRCIIDN
     NNLLVNELDF ADHGQDSSSL STSKSSEIEP KLDKKQDDLA PSETCLKKEL SQCNCIDLSK
     SPDPDKSTGT DCRSNLETES SHQSVCTDTS ATSCNCKATE DASDLNDDDN LPTQELYYVF
     DKFILTSGKP PTIVCSICKK DGHSKNDCPE DFRKIDLKPL PPMTNRFREI LDLVCKRCFD
     ELSPPCSEQH NREQILIGLE KFIQKEYDEK ARLCLFGSSK NGFGFRDSDL DICMTLEGHE
     NAEKLNCKEI IENLAKILKR HPGLRNILPI TTAKVPIVKF EHRRSGLEGD ISLYNTLAQH
     NTRMLATYAA IDPRVQYLGY TMKVFAKRCD IGDASRGSLS SYAYILMVLY FLQQRKPPVI
     PVLQEIFDGK QIPQRMVDGW NAFFFDKTEE LKKRLPSLGK NTESLGELWL GLLRFYTEEF
     DFKEYVISIR QKKLLTTFEK QWTSKCIAIE DPFDLNHNLG AGVSRKMTNF IMKAFINGRK
     LFGTPFYPLI GREAEYFFDS RVLTDGELAP NDRCCRVCGK IGHYMKDCPK RKSLLFRLKK
     KDSEEEKEGN EEEKDSRDVL DPRDLHDTRD FRDPRDLRCF ICGDAGHVRR ECPEVKLARQ
     RNSSVAAAQL VRNLVNAQQV AGSAQQQGDQ SIRTRQSSEC SESPSYSPQP QPFPQNSSQS
     AAITQPSSQP GSQPKLGPPQ QGAQPPHQVQ MPLYNFPQSP PAQYSPMHNM GLLPMHPLQI
     PAPSWPIHGP VIHSAPGSAP SNIGLNDPSI IFAQPAARPV AIPNTSHDGH WPRTVAPNSL
     VNSGAVGNSE PGFRGLTPPI PWEHAPRPHF PLVPASWPYG LHQNFMHQGN ARFQPNKPFY
     TQDRCATRRC RERCPHPPRG NVSE
//
